Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Leases (2019 - 2025)

Ligand Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $4.4 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 29.55% year-over-year to $4.4 million; the TTM value through Sep 2025 reached $4.4 million, down 29.55%, while the annual FY2024 figure was $5.8 million, 1.04% up from the prior year.
  • Operating Leases for Q3 2025 was $4.4 million at Ligand Pharmaceuticals, down from $4.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $27.1 million in Q2 2022 and bottomed at $2.3 million in Q4 2021.
  • The 5-year median for Operating Leases is $5.8 million (2023), against an average of $7.9 million.
  • The largest annual shift saw Operating Leases plummeted 84.15% in 2021 before it surged 467.76% in 2022.
  • A 5-year view of Operating Leases shows it stood at $2.3 million in 2021, then soared by 358.16% to $10.3 million in 2022, then plummeted by 44.32% to $5.8 million in 2023, then rose by 1.04% to $5.8 million in 2024, then dropped by 24.08% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Operating Leases are $4.4 million (Q3 2025), $4.6 million (Q2 2025), and $3.6 million (Q1 2025).